Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics Review uri icon

Overview

MeSH Major

  • Killer Cells, Natural
  • Neoplasm Metastasis
  • Neoplasms
  • Tumor Microenvironment

abstract

  • The expression "immunogenic cell death" (ICD) refers to a functionally unique form of cell death that facilitates (instead of suppressing) a T cell-dependent immune response specific for dead cell-derived antigens. ICD critically relies on the activation of adaptive responses in dying cells, culminating with the exposure or secretion of immunostimulatory molecules commonly referred to as "damage-associated molecular patterns". Only a few agents can elicit bona fide ICD, including some clinically established chemotherapeutics such as doxorubicin, epirubicin, idarubicin, mitoxantrone, bleomycin, bortezomib, cyclophosphamide and oxaliplatin. In this Trial Watch, we discuss recent progress on the development of ICD-inducing chemotherapeutic regimens, focusing on studies that evaluate clinical efficacy in conjunction with immunological biomarkers.

publication date

  • December 2, 2017

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC5706600

Digital Object Identifier (DOI)

  • 10.1080/2162402X.2017.1386829

PubMed ID

  • 29209573

Additional Document Info

start page

  • e1386829

volume

  • 6

number

  • 12